Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
批准号:
10411382
负责人:
Besim Ogretmen
金额:
$6.3万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-31 至 2023-07-31
关键词:
AffectAnimal ModelAttenuatedBardet-Biedl SyndromeBindingCell CommunicationCell membraneCellsCeramidesCiliaClinicalComplexDataDevelopmentGeneticGenetic ModelsGoalsHumanLigand BindingLinkLipidsMalignant - descriptorMalignant NeoplasmsMammary NeoplasmsMediatingMembraneMetabolismMolecularMouse Mammary Tumor VirusNeoplasm MetastasisPatientsPharmacologyPositioning AttributePrimary NeoplasmProteinsReceptor SignalingRegulationRoleSHH geneSignal PathwaySignal TransductionSpecimenSphingolipidsTGF-beta type I receptorTestingTherapeuticToxic effectTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsTumor Tissuebasecancer cellcell motilityclinically relevantdesigndihydroceramide desaturaseinnovationlipid metabolismmigrationnovelpreventreceptorrecruitresponsetooltraffickingtumor
中文摘要
摘要
转化生长因子β受体I/II(T?RI/II)信号在质膜上被激活
(PM)通过配体结合,诱导SMAD3/4依赖(规范)或独立的细胞迁移、侵袭
和/或转移。当Smad3/4被激活时,Smad7结合并抑制T?RI/II信号。初级纤毛是
在不影响细胞运动的情况下介导细胞间通讯和迁移/侵袭的PM突起
通过激活各种信号通路,如Sonic Hedgehog(Shh)。神经酰胺是一种具有生物活性的神经鞘糖脂
具有肿瘤抑制信号功能,神经酰胺合成酶4(CerS4)产生长链C18/20-
神经酰胺。然而,神经酰胺代谢、Smad7募集和TüRI/II之间的任何机制联系
在初级纤毛膜上调节肿瘤转移的信号仍不清楚。基于
我们的新的和未发表的初步数据,我们设计这个应用程序来测试一个新的假设
CerS4/神经酰胺通过Smad7选择性地抑制原纤毛膜上T?RI/II的转运和信号转导
以调节细胞的迁移、侵袭和/或转移。提出了以下具体目标:目标1)
明确神经酰胺通过Smad7调节T?RI/II信号的机制;目标2)确定
神经酰胺/Smad7抑制复合体调节T?RI/II转运至初级纤毛的机制;
目的3)剖析初级纤毛T?RI/II信号转导致癌的下游机制
CerS4/神经酰胺/Smad7轴改变与肿瘤转移的关系总体而言,基于我们在
癌症信号和脂质代谢,我们处于独特的位置来开发基于新机制的
选择性地靶向/抑制初级纤毛中TüRI/II信号的策略,这将有助于减弱
肿瘤转移不影响转化生长因子-B信号的典型功能(降低一般毒性),使用
创新的分子/药理学工具、遗传模型和临床标本。
英文摘要
SUMMARY
Transforming growth factor beta receptor type I/II (TßRI/II) signaling is activated on the plasma membrane
(PM) by ligand binding, inducing Smad3/4-dependent (canonical) or independent cell migration, invasion
and/or metastasis. While Smad3/4 activates, Smad7 binds and inhibits TßRI/II signaling. Primary cilia are
protrusions of PM that mediate cell-to-cell communication and migration/invasion without affecting cell motility
by activating various signaling pathways such as sonic hedgehog (Shh). Ceramide is a bioactive sphingolipid
with tumor suppressive signaling functions, and ceramide synthase 4 (CerS4) generates long chain C18/20-
ceramide. However, any mechanistic link between ceramide metabolism, Smad7 recruitment and TßRI/II
signaling at the primary cilium membrane for the regulation of tumor metastasis remains unknown. Based on
our novel and unpublished preliminary data, we designed this application to test a novel hypothesis that
CerS4/ceramide inhibits TßRI/II trafficking and signaling selectively at the primary cilia membrane via Smad7
to modulate cell migration, invasion and/or metastasis. The following Specific Aims are proposed: Aim 1)
Define the mechanisms by which ceramide regulates TßRI/II signaling by Smad7; Aim 2) Determine the
mechanisms by which ceramide/Smad7 inhibitory complex regulates TßRI/II trafficking to the primary cilia; and
Aim 3) Dissect the downstream mechanism by which TßRI/II signaling at primary cilia induces tumor
metastasis in response to alterations of the CerS4/ceramide/Smad7 axis. Overall, based on our expertise in
cancer signaling and lipid metabolism, we are uniquely positioned to develop novel mechanism-based
strategies for targeting/inhibiting TßRI/II signaling selectively in primary cilium, which then will help attenuate
tumor metastasis without affecting canonical functions of TGF-ß signaling (reducing general toxicity), using
innovative molecular/pharmacologic tools, genetic models, and clinical specimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting AML Mitochondria by Ceramide
-
批准号:10546239
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Besim Ogretmen
-
依托单位:
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
-
批准号:10253130
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2020
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
-
批准号:9930853
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2019
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
-
批准号:10801345
-
项目类别:
-
资助金额:$37.11万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9977980
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10222592
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10460230
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9441547
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9072008
-
项目类别:
-
资助金额:$181.11万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling
-
批准号:9072014
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9980696
-
项目类别:
-
资助金额:$174.77万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:8585322
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9269533
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9076632
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8714006
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8514026
-
项目类别:
-
资助金额:$105.65万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8305278
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:9098741
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
Lipidomics Shared Resource
-
批准号:10377471
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2009
-
负责人:Besim Ogretmen
-
依托单位:
Developmental Cancer Therapeutics
-
批准号:10589910
-
项目类别:
-
资助金额:$5.06万
-
财政年份:2009
-
负责人:Besim Ogretmen
-
依托单位:
海外基金